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Abstract
Background: Phytanic acid (PA) has been implicated in development of cancer and its defective metabolism is
known to cause life-threatening conditions, such as Refsum disease, in children. To explore molecular mechanisms
of phytanic acid-induced cellular pathology, we investigated its effect on NADPH oxidase (NOX) and epidermal
growth factor receptor (EGFR) in rat aortic smooth muscle cells (RASMC).
Methods: Smooth muscle cells were isolated from rat aortae using enzymic digestion with collagenase and
elastase. Cultured RASMC were treated with varying concentrations (0.5-10 μg/ml) of phytanic acid in the
presence/absence of fetal bovine serum (FBS) and/or EGFR inhibitor, AG1478. Following treatment with
experimental agents, NOX activity was assayed in RASMC cultures by luminescence method. Gene expression of
NOX-1 and p47phox was assessed using RT-PCR. NOX-1, p47phox and, total EGFR protein and its phosphorylated
form were measured by Western blotting.
Results: Treatment of RASMC with supraphysiological concentrations (>2.5 μg/ml) of PA significantly (p < 0.01)
increased the NOX activity. PA also significantly increased gene/protein expression of NOX-1 and p47phox whereas
p22phox and p67phox remained unaffected. Interestingly, PA (2.5-10 μg/ml) markedly (2–3 folds) increased the
total and phosphorylated EGFR. Treatment of cells with EGFR inhibitor, AG1478, significantly blocked the
PA-induced enhancement of NOX activity.
Conclusions: Our findings that PA transactivates EGFR and induces NOX activity in vascular smooth muscle cells
provide new insights into molecular mechanisms of PA’s role in cancer and Refsum disease.
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Background
Phytanic acid (PA) is a branched fatty acid that is syn-
thesized from phytol during degradation of plant chloro-
phyll and catabolized in mammalian cells through
peroxisome enzyme system [1, 2]. Major amount of cir-
culating phytanic acid in humans comes from dietary
sources such as meats and dairy products [3]. PA metab-
olism was recognized to be vital for human health with
the identification of peroxisomal disorders, such as
Zellweger syndrome and Refsum disease where supra-
physiological amounts of phytanic acid were found to
accumulate in body tissues and fluids of the patients
[4–6]. Peroxisomal disorder patients with aberrant
phytanic acid metabolism often experience severe
clinical complications that range neurological impair-
ment to cardiovascular anomalies [7, 8]. PA has been
reported to inhibit Na+, K+-ATPase activity and mito-
chondrial respiratory chain complex (s) possibly caus-
ing impairment of synaptic function [9, 10]. A
number of nuclear transcription factors called peroxi-
some proliferator-activated receptors (PPAR), particu-
larly PPAR-α, have strong affinity for PA and their
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activation through ligand binding affects lipid metab-
olism, besides other responses [11]. Idel and co-
workers [12] have reported that supraphysiological
levels of phytanic acid induce nitric oxide-mediated
apoptosis in cultured vascular smooth muscle cells
suggesting thereby that phytanic acid might have a
role in regulation of cell growth in vivo. Though ni-
tric oxide has recently been implicated in phytanic
acid-induced apoptosis of smooth muscle cells, any
role of reactive oxygen species such as highly reactive
superoxide anion production in relation to phytanic
acid-mediated regulation of vascular growth remains
to be examined. NADPH oxidase (NOX), a multicom-
ponent enzyme system, is a major source of super-
oxide anion formation in various tissues including
vascular smooth muscle cells [13, 14]. Though origin-
ally reported for its presence in phagocytes, NOX is
now known to be expressed in all vascular cell types
and participates in various physiological functions
such as regulation of vascular tone and pathological
conditions such as diabetes, hypertension and athero-
sclerosis [15–17]. In vascular smooth muscle cells,
NOX activity is regulated by a catalytic unit NOX-1
and several subunits such as p22phox, p47phox,
p67phox and rac-1, and one or more than one of
these components of NOX have been reported to be
modulated during different pathological conditions
[18, 19]. Though NOX system has been extensively
investigated and reported for its modulation by vari-
ous vasoactive molecules such as angiotensin-II,
PDGF and cytokines [20–22], it has remained unclear
if phytanic acid, a biomolecule linked with severe cel-
lular pathology in peroxisomal disease, has any influ-
ence on superoxide anion production by NOX.
Recently, increased serum levels of PA have been
linked to development of several types of cancers that
include prostate, breast and colon [23], however molecu-
lar mechanism (s) of PA-induced cellular pathology in
carcinogenesis remain unknown. Overproduction of re-
active oxygen species (ROS) has been reported as one of
the several culprits for development of cancer in humans
and NOX-mediated generation of ROS is known to con-
tribute towards formation of tumors [24, 25]. EGFR, a
cell surface receptor with intrinsic protein kinase activ-
ity, has been recognized as a key player in vascular biol-
ogy and, development and progression of cancer due to
its diverse signaling responses to regulate cellular prolif-
eration, differentiation, migration and survival [26, 27].
EGFR mutations and overexpression have been widely
linked to various types of cancers, leading the way to de-
velopment of EGFR inhibitors as anticancer agents [28].
PA-mediated risk of cancer has attracted the attention of
several research groups, yet any role of EGFR, a key cell
growth regulator, in PA-induced cellular pathology has
remained unexplored. This study was carried out to in-
vestigate the effect of PA on NOX and EGFR in vascular
smooth muscle cells, to understand cellular and molecu-
lar mechanisms of PA-induced pathogenesis in peroxi-
somal disorders and development of cancer. Vascular
smooth muscle cells have been used in previous studies
to examine PA-induced pathogenic effects. Vascular
smooth muscles were employed as an experimental
model in this study due to their well reported active par-
ticipation in lipid metabolism and their role in growth
factors-/receptors- and NOX-mediated pathogenesis in
proliferative vascular diseases.
Methods
Male Wistar Rats (weighing 100-125 g) were used in this
study according to the United States National Institute
of Health (NIH) guidelines for the Care and Use of La-
boratory Animals (NIH Publication No. 85–23, revised
in 1996). The study protocols (MK01/12) were approved
by the Research Ethics Committee of Health Sciences
Center, Kuwait University.
Materials
Bovine serum albumin (BSA), penicillin/streptomycin
and fetal bovine serum (FBS) were purchased from
Sigma Chemical Company (St. Louis, MO). DMEM-
Ham’s F-12 (1:1) and trypsin-EDTA were from GIBCO
(Grand Island, NY). Lucigenin, NADPH and phytanic
acid were purchased from Sigma Chemical Co. Primaria
tissue culture plates were obtained from Falcon Becton
Dickinson (Oxnard, CA). All other reagents were of
highest quality available and purchased from Sigma or
Calbiochem.
Methods
Aortic smooth muscle cell cultures
Rats were anesthetized with metofane and sacrificed by
ventricular puncture for the removal of thoracic aortae.
Aortic smooth muscle cells were cultured using enzymic
digestion of aortic tissue by collagenase and elastase as
described earlier [29]. Thoracic aortas were cleaned of
the adherent fatty tissue and washed with sterile Hank’s
medium. Aortas were then incubated for 20 min at 37 ° C
in the digestion mixture that contained 1.5 mg/ml BSA,
25U/ml of pancreatic Elastase (Sigma, USA) and 200U/ml
Collagenase (type IX, Sigma, USA). After the incubation
period, adventitia was removed and, the medial layer was
cut into small fragments and digested by incubation in di-
gestion mixture for another 45 min followed by washing
twice with fresh DMEM and centrifugation. Isolated
cells were suspended in DMEM-F12 HAM containing
10 % heat-inactivated fetal bovine serum and plated
onto 25-cm2 culture flasks for culture in humidified
conditions under 5 % CO2. The obtained RASMC
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were characterized by immunostaining with monoclo-
nal antibody specific for smooth muscle α-actin.
Treatment of cell cultures
Aortic smooth muscle cells grown in culture plates were
used in all experiments. Before adding the experimental
agents, cell monolayers were washed twice with serum
free DMEM-F/12 medium (SFM) and incubated at 37 °C
in a humidified cell culture incubator for 2 h in the pres-
ence of 0.1 % FBS containing DMEM-F/12 medium.
Phytanic acid (0–10 μg/ml) was mixed with α-
cyclodextrin-containing DMSO (0.001 % v/v) and added
to the cell cultures in the presence or absence of FBS
(5 %) and/or 50 μM of AG1478. Following the addition
of experimental agents, cells were incubated in cell
culture incubator for another 20–24 h at 37 °C.
Assay of NADPH oxidase activity
NADPH oxidase activity was measured in cell homoge-
nates at 37 °C using lucigenin and NADPH as described
elsewhere [30]. Briefly, NOX activity was measured in
cell homogenates in a reaction mixture that contained
50 mM phosphate buffer, pH 7.1, 0.01 mM EDTA and
25 μM lucigenin. Reaction was started by addition of
100 μM of NADPH and chemluminiscence was recorded
over a period of 3 min. Specific enzyme activity was
calculated as relative light units (RLU) emitted per sec
per mg of protein.
RNA isolation and reverse transcription
In each experiment, total RNA was extracted from
cultured smooth muscle cells with RNA extraction kit
based on use of guanidinium thiocyanate, lithium chlor-
ide and cesium triflouroacetate. Isolated RNA was of
high quality and was used immediately for synthesis of
first strand cDNA according to protocols from Clone-
tech’s SMART PCR cDNA synthesis kit.
PCR detection of mRNA for NOX-1, p22phox, p47phox,
p67phox and G3PDH
Amplification of cDNA obtained from reverse transcrip-
tion of RNAs from RASMCs was carried out using Ad-
vantage cDNA PCR kit (BD Biosciences Clonetech) and
the following primers: NOX-1; 5′-GCC AGA CTC AGA
GTT GGA GAT GCT–3′ and 5′-GCA GTT TCA AGA
TGC GTG GAA ACT A-3′, p22phox; 5′-GTA GAT
GCC GCT CGC AAT GGC CAG-3′ and 5′- ATG GGG
CAG ATC GAG TGG GCC ATG T-3′, p47phox; 5′-
CTT TGG GCA TCA AGT ATG TCT C-3′ and 5′-ATC
AAT CCA GAG AAC AGG ATC A-3′ and p67phox; 5′-
TGC CTT TTC CAG TAC TAC CTA TGT C-3′ and
5′-CTC TCA TCT GAC ACT CCC ATT TAA C-3′.
Primers for G3PDH were provided by Clonetech. First
strand of cDNA obtained from reverse transcription was
denatured for 1 min at 95 °C and subjected to PCR with
following parameters; 95 °C for 30 sec, 58 °C or 62 °C
for 30 sec, 68 °C for 45 sec, 25–30 cycles after denatur-
ing at 95 °C for 1 min. PCR products for various NOX
components were analyzed using 2 % agarose gel
electrophoresis.
Western blot analysis of NOX-1, p47 phox and EGFR
Western blotting for NOX-1, p47 phox and total or
phosphorylated forms of EGFR was performed as de-
scribed earlier [31]. Briefly, cell pellets were transferred
to lysis buffer (pH 7.6) containing 50 mM Tris-base,
5 mM EGTA, 150 mM NaCl, 1 % Triton 100, 2 mM
Na3VO4, 50 mM NAF, 1 mM PMSF, 20 μM phenylar-
sine, 10 mM sodium molybdate, 10 μg/ml leupeptin and
8 μg/ml aprotinin). Aliquots containing equal amounts
of protein were subjected to SDS-PAGE gel electrophor-
esis (SDS-PAGE) and transferred onto nitrocellulose
membrane. Monoclonal antibodies were used to detect
NOX-1, p47 phox and, phosphorylated and total forms
of EGFR. Secondary antibodies conjugated to horserad-
ish peroxidase were employed to get immunoreactive
bands that were detected with Super Signal chemilumin-
escent substrate. Images were finally analyzed and quan-
tified by densitometry and all data normalized to β-actin
levels.
Data analysis
Values shown in the results are mean ± standard deviation
of four experiments carried out in triplicate. Student’s t
test was employed using SPSS software to determine
statistical significance of the results.
Fig. 1 NADPH oxidase activity (shown as percent of control) in
cultured RASMC following treatment with 0–10 μg/ml of phytanic
acid in the presence (dark bars) or absence (light bars) of 5 % FBS.
Values are Mean ± SD of at least six measurements. *p < 0.01 when
compared with control (0 μg/ml of phytanic acid with or
without FBS)
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Results
Effect of Phytanic acid on NOX in RASMC cultures
Figure 1 shows that 24 h treatment of RASMC with
supra-physiological concentrations (2.5-10 μg/ml) of
phytanic acid significantly (p < 0.01) increased the NOX
activity irrespective of the presence or absence of FBS in
the culture medium. In relation to the observed activa-
tion of NOX activity by phytanic acid, we examined the
gene/protein expression and of various NOX compo-
nents in RASMC cultures treated with phytanic acid in
the presence or absence of FBS. Figure 2 shows the re-
sults of PCR analysis of NOX-1, the catalytic unit of
NOX and sub-component p47phox in smooth muscle
cells following treatment with PA and or FBS. PCR ana-
lysis illustrated in Fig. 2b shows that the ratios of the
levels of NOX-1 or p47phox gene transcripts and
GAPDH were significantly increased (p <0.01) in
RASMC treated with phytanic acid (5 μg/ml) in the
presence or absence of 5 % FBS. Stimulation of cells with
FBS–alone did not have any significant effect on the
gene transcripts of NOX-1, however p47phox was sig-
nificantly (p < 0.01) elevated. Protein levels of NOX-1 as
well as p47phox were markedly increased following
treatment of RASMC with phytanic acid in the presence
or absence of FBS (Fig. 3). Phytanic acid treatment, how-
ever did not have any significant effect on gene expres-
sion of p22phox or p67phox in RASMC cultures (data
not shown).
Effect of phytanic acid on EGFR
Figure 4 shows that treatment of RASMC with supra-
physiological concentrations (2.5 -10 μg/ml) of phytanic
acid significantly (p < 0.01) increased the expression of
total EGFR protein in the presence or absence of FBS.
Phytanic acid also significantly (p < 0.01) enhanced the
phosphorylation of EGFR, however the effect was more
pronounced in cells treated with 10 μg/ml of PA in the
presence of FBS.
Effect of AG1478 on PA-induced NOX activity
EGFR specific inhibitor, AG1478, significantly (p < 0.01)
blocked the PA-induced NOX activity as shown in Fig. 5.
FBS did not have any significant effect on NOX activity
in the presence or absence of PA and/or AG1478.
Discussion
A marked increase in the levels of phytanic acid in body
tissues and fluids of patients with Refsum disease and
Zellweger syndrome has, for many years, implicated this
branched fatty acid in development and progression of
the disease [4, 5], yet the underlying molecular mecha-
nisms of such a role for PA in pathogenesis of peroxi-
somal diseases have remained elusive. More recently,
increased levels of PA have been linked with an in-
creased risk of developing cancer [25], however patho-
genic mechanisms have remained unidentified. This
Fig. 2 Gene expression of NOX-1 and p47phox in RASMC cultured
in serum free medium (lane 1) or 5 μg/ml of phytanic acid (lane 2)
or 5 % FBS (lane 3) or FBS and phytanic acid (lane 4). Panel A shows
the representative bands for mRNA levels of NOX-1, p47 phox and
GAPDH. Panel B shows the percent ratio of NOX/GAPDH or
p47phox/GAPDH in RASMC. Values are Mean ± SD of at least six
measurements. *p < 0.01 when compared with control (without FBS
or phytanic acid)
Fig. 3 Western blot analysis of NOX-1 and p47phox in RASMC
cultures treated with serum free medium (lane 1) or 5 μg/ml of
phytanic acid (lane 2) or 5 % FBS (lane 3) or FBS and phytanic acid
(lane 4). Panel A shows the representative protein bands of NOX-1,
p47 phox and actin. Panel B shows the ratio of NOX/actin or
p47phox/actin in RASMC. Values are Mean ± SD of at least six
measurements. *p < 0.01 when compared with control (lane 1)
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study provides some new insights into molecular mecha-
nisms of PA-mediated cellular pathology.
Besides several other mechanisms suggested for the
regulation of cellular functions by different fatty acids,
intracellular production of or exposure to extracellular
cytokines, reactive oxygen species and nitric oxide pro-
duction have been reported to mediate fatty acid–induced
effects on cell survival [32, 33]. The supraphysiological
concentrations of phytanic acid have been shown earlier
to enhance nitric oxide production in vascular smooth
muscle cells and induce apoptosis [12]. Nitric oxide is an
important regulator of vascular biology and has been
widely reported to inhibit vascular growth in vivo as well
as in cell culture studies [34]. Nitric oxide-mediated
effects have been reported to be influenced by the super-
oxide anion production, as these two species interact to
generate a highly reactive peroxynitrite molecule [35]. Our
findings that PA activates NOX activity through upregula-
tion of NOX-1 and p47phox proteins, strongly suggests
that nitric oxide may not be the only reactive nitrogen/
oxygen species formed in response to phytanic acid,
superoxide formation as a result of NOX activation, may
well be a key ROS produced in response to PA that may
further lead to formation of highly reactive peroxynitrite.
ROS, such as superoxide radicals and hydrogen peroxide
have been reported earlier to modulate the proliferation of
smooth muscle cells in vivo as well as in vitro studies [36].
Enzymatic activity of NOX has been well reported to be
regulated through interaction of its various components,
p22phox, p47phox and p67phox. Our findings that phyta-
nic acid enhances NOX-1 and p47phox levels through
transcriptional and translational activation without having
any significant effect on expression of p22 phox and
p67phox proteins indicate that this branched fatty acid
possibly plays a role in regulation of cellular oxidative
stress through activation of NOX and thus provides a
novel molecular mechanism for the actions of phytanic
acid in conditions of peroxisomal dysfunction or carcino-
genesis. Our finding that PA-induced enhancement of
NOX activity is partly blocked by AG1478, an EGFR in-
hibitor, unravels the involvement of EGFR, another key
cell growth regulator, in PA-mediated pathogenic events.
Over expression of EGFR is associated with cancer devel-
opment. The fact that PA increased the expression of
EGFR protein and enhanced its phosphorylation strongly
indicates that the reported carcinogenic capability of PA
in various types of cancers is likely occurring through acti-
vation of EGFR tyrosine kinase.
Impairment of the PA-induced NOX activity by EGFR
inhibitor strongly suggests that induction of EGFR gene
expression and phosphorylation of EGFR precede the ac-
tivation of NOX activity in response to ex vivo treatment
of RASMC with PA. Future in vivo studies might pro-
vide physiological importance of our findings however,
Fig. 5 NOX activity in RASMC cultures following treatment with
phytanic acid (10 μg/ml) and/or FBS (5 %) in the absence (open
bars) or presence (shaded bars) of EGFR inhibitor, AG1478 (50 μM).
Values of NOX activity shown as percent of Control are Mean ± SD
of six measurements. * p < 0.01 when compared with Control
(without FBS and PA)
Fig. 4 Panel a illustrates representative western blots of total
EGFR protein (t-EGFR), phosphorylated EGFR (p-EGFR) and Actin
in RASMC cultures. Panel b shows the levels of t-EGFR and panel
C illustrates the ratio of p-EGFR/t-EGFR in RASMC treated with
2.5 μg/ml (lane 2), 5.0 μg/ml (lane 3) or 10 μg/ml (lane 4) of
Phytanic acid. Lane 1 represents RASMC without any treatment
whereas lane 5 had RASMC treated with 10 μg/ml of PA and
5 % FBS. Values are Mean ± SD of six measurements. * p < 0.1
when compared with control (lane 1)
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this ex vivo study on RASMC cultures establishes an
important link between PA-induced transactivation of
EGFR and formation of NOX-mediated ROS production
providing a possible molecular mechanism of cellular
pathology of peroxisomal dysfunction in cases of Refsum
disease and PA-related carcinogenesis.
Conclusions
This ex vivo study carried out on vascular smooth muscle
cells concludes that PA increases NOX activity through
transcriptional activation of NOX-1 and p47phox. An in-
crease in phosphorylation of EGFR by PA and attenuation
of PA-induced NOX activity by EGFR inhibitor provide an
important insight into molecular mechanism of PA's role
in pathogenesis of some peroxisomal diseases and cancers.
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